GMP Issues: Moving QA onto the Manufacturing Floor - - BioPharm International


GMP Issues: Moving QA onto the Manufacturing Floor

BioPharm International

Quality assurance on the floor is the intention of many QA departments, but implementing the idea is often deferred for months or even years. How can QA help support manufacturing? And is it true that additional QA staff must be added to meet this goal?

QA review may be performed "off the floor" by reviewing production-generated GMP documents. Commonly, a production supervisor or manager reviews and corrects any errors or omissions. QA is thus a final check for compliance, occurring just before lot disposition.

Quality "on the floor" involves stationing QA people on the floor during production to assist and support the manufacturing staff in detecting and solving compliance errors in real time. In theory, cycle time is saved, failure investigations are more likely to be effective (because all physical samples still exist), and QA-to-manufacturing communication is enhanced.

The Fantasy of QA on the Floor Perhaps the difficulty lies in everyone seeing the QA presence on the floor as a panacea. For instance, a production person may see this as an opportunity to obtain on-the-spot permission for any kind of planned deviation, thereby avoiding that pesky paperwork and long wait for approval before moving forward. The QA person may see an opportunity to get some auditing work accomplished before the next planned audit. Management sees an opportunity to increase communication among groups, improve teamwork, and accelerate problem resolution.

All of these are highly desirable outcomes. Having the ability to approve deviations rapidly can help move an unstable product intermediate quickly to the next step. Failure investigations can begin when the evidence is available and intact. There is likely to be less second-guessing later when a team decides together on urgency, approach, and importance. And a QA person who spends more time on the floor will certainly gain a more accurate picture of the actual level of compliance than a person who appears for a day or two once a year. How effective can feedback on documentation be if it is given three months after a batch is completed on the floor? By that time, the error has likely been repeated on other batches and is becoming a habit.

So what are the challenges? Some QA colleagues will tell you that making it easy to deviate amounts to condoning or encouraging deviations. This bureaucratic logic assumes that making a process difficult is an effective method to discourage its frequent use. There is a grain of truth in this, but perhaps other methods are better.

One difficulty in making the human-in-plant strategy work is the variety and gravity of issues that can suddenly arise. The QA person may not have the experience to make good decisions quickly in all cases. Given time, and the intervention of people who are a bit remote from the floor, a different decision might be made. Some events are critical and will always need to be referred to the next management level for resolution. So how do you make the QA person useful, even when they are not godlike, infallible, and fully empowered for absolutely everything?

The Bogeyman of QA on the Floor Any member of QA can be perceived as a cop or a judge who has the power to make production and QC staff do more work and justify their actions. The QA team should discuss this stereotype and address these concerns before launching a QA-on-the-floor program.

"I feel like you treat us as if we are guilty until proven innocent," says one production supervisor. Pointing out that an FDA or European inspector might make the same assumption does not seem to mitigate such feelings. Yet, other staff are likely to say, "Please come in. I want to show you how we do this and get your input."

Can a QA person be of real assistance, given this dual role of judge and counselor? Yes, however, careful support and training are needed for both QA and production staff, and realistic and clear project goals must be set. Don’t expect a QA presence to solve everything.

Essentially, the role of person-in-plant is to prevent compliance problems from occurring or to nip them in the bud and handle them appropriately. This person is valuable when you have relatively inexperienced production and QC staff — a condition that plagues process development and clinical manufacturing. When everyone is somewhat unfamiliar with the batch record, the procedures, or the new equipment, it is helpful to have someone checking the work and giving feedback. This person can be a member of the quality group conversant in the current practices acceptable to reviewers. The QA person can advise on how best to document a deviation, how to correct an entry, or what wording to use without creating more problems. A QA person can contact management on your behalf, approve planned deviations, and make notes for improving a document at a later date. They may even check calculations if they are properly trained. If QA staff have technical backgrounds, they can participate in troubleshooting and brainstorming. If not, they can draw out the technical people to articulate what experience or data lie behind a "gut feeling."

What about commercial product settings or routine production? The veteran operator may be so familiar with CGMP procedures and batch records that documents have not been read carefully for some time. This person may benefit from spot checks by colleagues or the QA person-in-plant. A process can drift as a result of staff innovations to existing procedures; perhaps the SOP needs updating. Such QA spot checks are ideally placed to reinforce recent training or new procedures. Random spot checks can be used for monitoring overall quality. In practice, spot checks occur when staff are available, and the results are extrapolated to other critical process points, whether appropriate or not.

blog comments powered by Disqus



Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines
Source: BioPharm International,
Click here